Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

Completed · Phase 2

Conditions studied: Carcinoma, Non-small-cell Lung

In brief

The purpose of this trial is to study how long patients can remain progression free when they receive CP-675,206, compared to how long patients can remain progression free when they receive best supportive care. If you choose to take part, you will be randomized to receive either CP-675,206 as maintenance therapy or best supportive care. Best supportive care means you will not receive any study drug or other treatment for your cancer. Best supportive care could include treatment with antibiotics, analgesic drugs (medicine for pain), blood transfusions or psychosocial and nutritional support, depending on your needs. You have a 50% chance of being randomized to receive CP-675,206.

Key facts

Study ID

NCT00312975

Run by

AstraZeneca

People needed

90

Starts

2006-05-01

Expected to finish

2010-02-01

Last updated by the study team

2012-06-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stage IIIb (with effusion) or stage IV disease that has responded or remained stable after 6 cycles of a platinum containing 1st-line regimen
• Patients must be able to be randomized between 3 and no more than 6 weeks after the last dose of first-line therapy.

You may not qualify if…

• No other systemic therapy except 1st-line platinum based treatment
• Symptomatic or uncontrolled brain mets or uncontrolled pleural effusions.

Where it is running

• Research Site — Bentonville, Arkansas, United States
• Research Site — Fayetteville, Arkansas, United States
• Research Site — Orange, California, United States
• Research Site — Danbury, Connecticut, United States
• Research Site — Atlanta, Georgia, United States
• Research Site — Lexington, Kentucky, United States
• Research Site — Alexandria, Louisiana, United States
• Research Site — New York, New York, United States
• Research Site — Oneida, New York, United States
• Research Site — Oswego, New York, United States
• Research Site — Syracuse, New York, United States
• Research Site — Syracuse, New York, United States
• Research Site — Canton, Ohio, United States
• Research Site — Philadelphia, Pennsylvania, United States
• Research Site — Calgary, Alberta, Canada
• Research Site — Calgary, Alberta, Canada
• Research Site — Edmonton, Alberta, Canada
• Research Site — Montreal, Quebec, Canada
• Research Site — Prague, Czechia
• Research Site — Tábor, Czechia
• Research Site — Ústí nad Labem, Czechia
• Research Site — Seoul, South Korea
• Research Site — Seoul, South Korea
• Research Site — Seoul, South Korea
• Research Site — Southampton, Hampshire, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.